ADMA Biologics (ADMA) News Today

ADMA Biologics, Inc. (NASDAQ: ADMA) — Shares moved lower today after mixed first-quarter results and a weaker-than-expected 2026 revenue outlook offset positive clinical/regulatory news and strong cash generation. Volume spiked as investors digested an EPS that met estimates but a sizable revenue miss, a lowered FY revenue guide, and multiple securities-law investigations announced by plaintiff firms.

• Positive Sentiment: FDA label expansion broadens pediatric market for ASCENIV, increasing addressable patients and long‑term upside for product sales. ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label
• Positive Sentiment: Q1 operational strength: ASCENIV revenue grew ~28% Y/Y, adjusted net income and adjusted EBITDA both rose, and cash from operations was strong — evidence of durable demand and near-term cash generation. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Q1 reported EPS of $0.19 matched consensus but total revenue of $114.5M missed street estimates (~$140M), a mixed print that limited upside despite profitability metrics. View Press Release
• Negative Sentiment: ADMA lowered FY‑2026 revenue guidance to $530M–$560M vs. consensus ~ $625M and withdrew long‑term guidance, signaling a weaker top‑line outlook and creating near‑term downside risk to the stock. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Multiple securities‑law firms announced investigations and encouraged investors to contact them over alleged misleading disclosures and the recent share decline — heightening litigation risk and investor uncertainty. ADMA Investor News - Rosen Law Firm Investigation BFA Law Investigation Notice

Investor takeaway: Positive catalysts (FDA label expansion, ASCENIV growth, strong cash flow) support medium/long‑term upside, but the Q1 revenue miss, lowered FY revenue guide and active litigation inquiries are driving near‑term selling pressure. Monitor upcoming conference call commentary, actual execution versus the new guide, and any legal developments for directional cues.